1
|
Bullement A, Kearns B. Incorporating external trial data to improve survival extrapolations: a pilot study of the COU-AA-301 trial. HEALTH SERVICES AND OUTCOMES RESEARCH METHODOLOGY 2022. [DOI: 10.1007/s10742-021-00264-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
AbstractSurvival extrapolation plays a key role within cost effectiveness analysis and is often subject to substantial uncertainty. Use of external data to improve extrapolations has been identified as a key research priority. We present findings from a pilot study using data from the COU-AA-301 trial of abiraterone acetate for metastatic castration-resistant prostate cancer, to explore how external trial data may be incorporated into survival extrapolations. External trial data were identified via a targeted search of technology assessment reports. Four methods using external data were compared to simple parametric models (SPMs): informal reference to external data to select appropriate SPMs, piecewise models with, and without, hazard ratio adjustment, and Bayesian models fitted with a prior on the shape parameter(s). Survival and hazard plots were compared, and summary metrics (point estimate accuracy and restricted mean survival time) were calculated. Without consideration of external data, several SPMs may have been selected as the ‘best-fitting’ model. The range of survival probability estimates was generally reduced when external data were included in model estimation, and external hazard plots aided model selection. Different methods yielded varied results, even with the same data source, highlighting potential issues when integrating external trial data within model estimation. By using external trial data, the most (in)appropriate models may be more easily identified. However, benefits of using external data are contingent upon their applicability to the research question, and the choice of method can have a large impact on extrapolations.
Collapse
|
2
|
Proença CA, Freitas TA, Baldo TA, Materón EM, Shimizu FM, Ferreira GR, Soares FLF, Faria RC, Oliveira ON. Use of data processing for rapid detection of the prostate-specific antigen biomarker using immunomagnetic sandwich-type sensors. BEILSTEIN JOURNAL OF NANOTECHNOLOGY 2019; 10:2171-2181. [PMID: 31807403 PMCID: PMC6880837 DOI: 10.3762/bjnano.10.210] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/02/2019] [Accepted: 10/07/2019] [Indexed: 05/03/2023]
Abstract
Diagnosis of cancer using electroanalytical methods can be achieved at low cost and in rapid assays, but this may require the combination with data treatment for determining biomarkers in real samples. In this paper, we report an immunomagnetic nanoparticle-based microfluidic sensor (INμ-SPCE) for the amperometric detection of the prostate-specific antigen (PSA) biomarker, the data of which were treated with information visualization methods. The INμ-SPCE consists of eight working electrodes, reference and counter electrodes. On the working electrodes, magnetic nanoparticles with secondary antibodies with the enzyme horseradish peroxidase were immobilized for the indirect detection of PSA in a sandwich-type procedure. Under optimal conditions, the immunosensor could operate within a wide range from 12.5 to 1111 fg·L-1, with a low detection limit of 0.062 fg·L-1. Multidimensional projections combined with feature selection allowed for the distinction of cell lysates with different levels of PSA, in agreement with results from the traditional enzyme-linked immunosorbent assay. The approaches for immunoassays and data processing are generic, and therefore the strategies described here may provide a simple platform for clinical diagnosis of cancers and other types of diseases.
Collapse
Affiliation(s)
- Camila A Proença
- Chemistry Department, Federal University of São Carlos, CP 676, São Carlos 13565-905, São Paulo, Brazil
| | - Tayane A Freitas
- Chemistry Department, Federal University of São Carlos, CP 676, São Carlos 13565-905, São Paulo, Brazil
| | - Thaísa A Baldo
- Chemistry Department, Federal University of São Carlos, CP 676, São Carlos 13565-905, São Paulo, Brazil
| | - Elsa M Materón
- Chemistry Department, Federal University of São Carlos, CP 676, São Carlos 13565-905, São Paulo, Brazil
- São Carlos Institute of Physics, University of São Paulo, CP 369, São Carlos 13560-970, São Paulo, Brazil
| | - Flávio M Shimizu
- São Carlos Institute of Physics, University of São Paulo, CP 369, São Carlos 13560-970, São Paulo, Brazil
- Brazilian Nanotechnology National Laboratory (LNNano), Brazilian Center for Research in Energy and Materials (CNPEM), Campinas 13083-970, São Paulo, Brazil
| | - Gabriella R Ferreira
- Carlos Institute of Chemistry, University of São Paulo, São Carlos 13560-970, São Paulo, Brazil
| | - Frederico L F Soares
- Chemistry Department, Federal University of São Carlos, CP 676, São Carlos 13565-905, São Paulo, Brazil
- Chemistry Department, Federal University of Paraná, Curitiba, 81531-980, Paraná, Brazil
| | - Ronaldo C Faria
- Chemistry Department, Federal University of São Carlos, CP 676, São Carlos 13565-905, São Paulo, Brazil
| | - Osvaldo N Oliveira
- São Carlos Institute of Physics, University of São Paulo, CP 369, São Carlos 13560-970, São Paulo, Brazil
| |
Collapse
|
3
|
The PTTG1-targeting miRNAs miR-329, miR-300, miR-381, and miR-655 inhibit pituitary tumor cell tumorigenesis and are involved in a p53/PTTG1 regulation feedback loop. Oncotarget 2016; 6:29413-27. [PMID: 26320179 PMCID: PMC4745736 DOI: 10.18632/oncotarget.5003] [Citation(s) in RCA: 63] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2015] [Accepted: 07/27/2015] [Indexed: 12/23/2022] Open
Abstract
Deregulation of the pituitary tumor transforming gene (PTTG1), a newly discovered oncogene, is a hallmark of various malignancies, including pituitary tumors. However, the mechanisms regulating PTTG1 expression are still needed to be explored. MicroRNAs (miRNAs) are a novel class of small RNA molecules that act as posttranscriptional regulators of gene expression and can play a significant role in tumor development. Here, we identified a series of miRNAs, namely, miR-329, miR-300, miR-381 and miR-655, which could target PTTG1 messenger RNA and inhibit its expression. Interestingly, all four miRNAs significantly that are downregulated in pituitary tumors were mapped to the 14q32.31 locus, which acts as a tumor suppressor in several cancers. Functional studies show that the PTTG1-targeting miRNAs inhibit proliferation, migration and invasion but induce apoptosis in GH3 and MMQ cells. Furthermore, overexpression of a PTTG1 expression vector lacking the 3′UTR partially reverses the tumor suppressive effects of these miRNAs. Next, we identified the promoter region of PTTG1-targeting miRNAs with binding sites for p53. In our hands, p53 transcriptionally activated the expression of these miRNAs in pituitary tumor cells. Finally, we found that PTTG1 could inhibit p53 transcriptional activity to the four miRNAs. These data indicate the existence of a feedback loop between PTTG1 targeting miRNAs, PTTG1 and p53 that promotes pituitary tumorigenesis. Together, these findings suggest that these PTTG1-targeting miRNAs are important players in the regulation of pituitary tumorigenesis and that these miRNAs may serve as valuable therapeutic targets for cancer treatment.
Collapse
|
4
|
Allina DO, Kekeeva TV, Moskvina LV, Shikeeva AA, Andreeva YY, Zavalishina LE, Frank GA. [Diagnostic value of estimation of ERG expression in prostate adenocarcinoma and high-grade prostatic intraepithelial neoplasia]. Arkh Patol 2015; 77:36-42. [PMID: 26978019 DOI: 10.17116/patol201577536-42] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
OBJECTIVE to estimate the diagnostic and prognostic value of analyzing the abnormal overexpression of the chimeric protein ERG, encoded by the chimeric gene TMPRSS2/ERG, in prostatic neoplasias. MATERIAL AND METHODS A total of 100 prostate adenocarcinoma samples were examined. The presence of tumor and high-grade prostatic intraepithelial neoplasia (hPIN) was verified by immunohistochemical tests using anti-P504S and anti-34βE12 antibodies in serial sections; RT-PCR was employed to analyze the chimeric transcript TMPRSS2/ERG in 30 prostate adenocarcinoma samples. RESULTS ERG expression was noted in 46% of the adenocarcinomas and in 21% of hPIN. Eight (8%) patients were observed to have heterogeneous ERG expression: the marked reaction in some tumor portions was concurrent with its complete absence in others. Furthermore, there was ERG expression in all cases of intraductal (noninvasive) carcinoma (the foci of intraductal carcinoma were assessed as atypical cribriform lesions by light microscopy). The prognostic value of ERG expression could not be determined at the current stage of the investigation. CONCLUSION The relatively low rate of ERG-positive hPIN counts in favor of the limited role of this marker in the differential diagnosis of hPIN. ERG in combination with P504S and 34βE12 is an informative marker for the differential diagnosis of hPIN with intraductal carcinoma.
Collapse
Affiliation(s)
- D O Allina
- Russian Medical Academy of Postgraduate Education, Moscow
| | - T V Kekeeva
- Russian Medical Academy of Postgraduate Education, Moscow; Research Centre for Medical Genetics, Moscow
| | | | - A A Shikeeva
- Russian Medical Academy of Postgraduate Education, Moscow; Research Centre for Medical Genetics, Moscow
| | - Yu Yu Andreeva
- Russian Medical Academy of Postgraduate Education, Moscow
| | | | - G A Frank
- Russian Medical Academy of Postgraduate Education, Moscow
| |
Collapse
|
5
|
Formosa A, Markert EK, Lena AM, Italiano D, Finazzi-Agro' E, Levine AJ, Bernardini S, Garabadgiu AV, Melino G, Candi E. MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene 2013; 33:5173-82. [PMID: 24166498 DOI: 10.1038/onc.2013.451] [Citation(s) in RCA: 248] [Impact Index Per Article: 22.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2013] [Revised: 07/24/2013] [Accepted: 08/09/2013] [Indexed: 12/26/2022]
Abstract
miRNAs act as oncogenes or tumor suppressors in a wide variety of human cancers, including prostate cancer (PCa). We found a severe and consistent downregulation of miRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 region in metastatic cell lines as compared with normal prostatic epithelial cells (PrEC). In specimens of human prostate (28 normals, 99 primary tumors and 13 metastases), lower miRNA levels correlated significantly with a higher incidence of metastatic events and higher prostate specific antigen (PSA) levels, with similar trends observed for lymph node invasion and the Gleason score. We transiently transfected 10 members of the 14q32.31 cluster in normal prostatic epithelial cell lines and characterized their affect on malignant cell behaviors, including proliferation, apoptosis, migration and invasion. Finally, we identified FZD4, a gene important for epithelial-to-mesenchymal transition in (PCa), as a target of miR-377.
Collapse
Affiliation(s)
- A Formosa
- 1] University of Tor Vergata, Department Experimental Medicine and Surgery, Rome, Italy [2] IDI-IRCCS, Rome, Italy
| | - E K Markert
- The Simons Center for Systems Biology, Institute for Advanced Study, Princeton, NJ, USA
| | - A M Lena
- University of Tor Vergata, Department Experimental Medicine and Surgery, Rome, Italy
| | - D Italiano
- University of Tor Vergata, Department Experimental Medicine and Surgery, Rome, Italy
| | - E Finazzi-Agro'
- University of Tor Vergata, Department Experimental Medicine and Surgery, Rome, Italy
| | - A J Levine
- The Simons Center for Systems Biology, Institute for Advanced Study, Princeton, NJ, USA
| | - S Bernardini
- University of Tor Vergata, Department Experimental Medicine and Surgery, Rome, Italy
| | - A V Garabadgiu
- Laboratory of Molecular Pharmacology, Saint-Petersburg Technological Institute, 26 Moskovsky Prospect, Petersburg, Russia
| | - G Melino
- 1] University of Tor Vergata, Department Experimental Medicine and Surgery, Rome, Italy [2] IDI-IRCCS, Rome, Italy
| | - E Candi
- University of Tor Vergata, Department Experimental Medicine and Surgery, Rome, Italy
| |
Collapse
|
6
|
Saito T, Hara N, Kitamura Y, Komatsubara S. Prostate-Specific Antigen/Prostatic Acid Phosphatase Ratio Is Significant Prognostic Factor in Patients with Stage IV Prostate Cancer. Urology 2007; 70:702-5. [DOI: 10.1016/j.urology.2007.05.019] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2006] [Revised: 03/30/2007] [Accepted: 05/22/2007] [Indexed: 01/29/2023]
|
7
|
Buhmeida A, Pyrhönen S, Laato M, Collan Y. Prognostic factors in prostate cancer. Diagn Pathol 2006; 1:4. [PMID: 16759347 PMCID: PMC1479371 DOI: 10.1186/1746-1596-1-4] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2006] [Accepted: 04/03/2006] [Indexed: 02/05/2023] Open
Abstract
Prognostic factors in organ confined prostate cancer will reflect survival after surgical radical prostatectomy. Gleason score, tumour volume, surgical margins and Ki-67 index have the most significant prognosticators. Also the origins from the transitional zone, p53 status in cancer tissue, stage, and aneuploidy have shown prognostic significance. Progression-associated features include Gleason score, stage, and capsular invasion, but PSA is also highly significant. Progression can also be predicted with biological markers (E-cadherin, microvessel density, and aneuploidy) with high level of significance. Other prognostic features of clinical or PSA-associated progression include age, IGF-1, p27, and Ki-67. In patients who were treated with radiotherapy the survival was potentially predictable with age, race and p53, but available research on other markers is limited. The most significant published survival-associated prognosticators of prostate cancer with extension outside prostate are microvessel density and total blood PSA. However, survival can potentially be predicted by other markers like androgen receptor, and Ki-67-positive cell fraction. In advanced prostate cancer nuclear morphometry and Gleason score are the most highly significant progression-associated prognosticators. In conclusion, Gleason score, capsular invasion, blood PSA, stage, and aneuploidy are the best markers of progression in organ confined disease. Other biological markers are less important. In advanced disease Gleason score and nuclear morphometry can be used as predictors of progression. Compound prognostic factors based on combinations of single prognosticators, or on gene expression profiles (tested by DNA arrays) are promising, but clinically relevant data is still lacking.
Collapse
Affiliation(s)
- A Buhmeida
- Departments of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland
| | - S Pyrhönen
- Departments of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland
| | - M Laato
- Departments of Surgery, Turku University Hospital, Turku, Finland
| | - Y Collan
- Departments of Pathology, Turku University Hospital, Turku, Finland
| |
Collapse
|